Zymeworks (ZYME)
(Delayed Data from NSDQ)
$8.58 USD
+0.25 (3.00%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $8.58 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth B Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ZYME 8.58 +0.25(3.00%)
Will ZYME be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ZYME based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZYME
3 Top Stocks to Invest in for Amazing Earnings Acceleration
Zymeworks (ZYME) Loses -13.41% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
ZYME: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks (ZYME) Upgraded to Buy: What Does It Mean for the Stock?
Zymeworks Inc. (ZYME) Reports Q4 Loss, Misses Revenue Estimates
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q4 Earnings? What You Should Know
Other News for ZYME
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Engages in Key Investor Conferences
Jazz Pharmaceuticals: Cheap But Complicated
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
ZYME Crosses Below Key Moving Average Level